NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CAR-T 細胞療法市場:第 3 版

CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others),

出版商 Roots Analysis 商品編碼 1008224
出版日期 內容資訊 英文 770 Pages
商品交期: 最快1-2個工作天內
價格
CAR-T 細胞療法市場:第 3 版 CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others),
出版日期: 2021年03月31日內容資訊: 英文 770 Pages
簡介

據世界衛生組織 (WHO) 稱,預計未來 20 年全球新診斷的癌症病例數將增加 70%。免疫療法,尤其是基於 T 細胞的產品,已證明其具有選擇性靶向和消除腫瘤細胞的能力,並已成為一種可行且有前景的治療選擇。事實上,CAR-T細胞療法目前被認為是可用於治療各種類型惡性血液腫瘤和實體瘤的最有前景的療法之一。

本報告研究和分析 CAR-T 細胞治療市場,並提供有關當前市場狀況和未來潛力的系統信息。

目錄

第一章前言

第 2 章執行摘要

第 3 章介紹

第 4 章社交媒體的新興趨勢

  • 章節概述
  • CAR-T 細胞療法:Twitter 趨勢

第五章市場情況

  • 章節概述
  • CAR-T 細胞療法:整體市場形勢

第 6 章主要討論

  • 章節概述
  • CAR-T 細胞治療競爭分析:按流行的靶抗原
  • CAR-T 細胞療法:KOL
  • CAR-T 細胞療法:CAR 成分分析

第7章臨床試驗分析

  • 章節概述
  • CAR-T 細胞療法:臨床試驗分析

第8章CAR-T細胞治療概況

  • 章節概述
  • KYMRIAH (R)/Tisagenlecleucel/CTL019 (Novartis)
  • YESCARTA (R)/Axicabtagene Cilouleucel/KTE-C19 (Kite Pharma)
  • TECARTUS (R)/Brexucabtagene Autoleucel (Kite Pharma)
  • JCAR(Juno Therapeutics(百時美施貴寶公司))
  • Idecabtagene Vicleucel/bb2121 (bluebird bio/Bristol-Myers Squibb)
  • Ciltacabtagene Autoleucel/LCAR-B38M CAR-T/JNJ-68284528(南京傳奇生物科技/楊森生物科技)
  • TBI-1501/CD19 CAR-T 細胞療法(寶生物)
  • 下一代 CAR-T 細胞療法 (Autolus)
  • CAR-T細胞療法(Sinobioway細胞療法)

第九章CAR-T細胞療法的主要治療領域

  • 章節概述
  • 惡性血液腫瘤
  • 實體瘤

第 10 章新興技術

  • 章節概述
  • 基因組編輯技術
  • 設計具有改進特性的 CAR-T 細胞療法

第 11 章夥伴關係和協作

第12章融資/投資分析

第13章案例研究:細胞療法的製造

第14章成本分析

第15章市場規模和機會分析

  • 章節概述
  • 範圍和限制
  • 主要前提和預測方法
  • CAR-T 細胞療法整體市場

第16章促銷分析

第17章公司簡介

  • 章節概述
  • Autolus
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene (A Bristol Myers Squibb Company)
  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Kite Pharma (A Gilead Sciences Company)
  • Kuur Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Shanghai Genechem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Ziopharm Oncology

第18章 結論

第19章 高管洞察力

第20章 附錄1:表格數據

第21章 附錄 2:公司/組織名單

目錄

Title:
CAR-T Cell Therapies Market (3rd Edition)
by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Industry Trends and Global Forecasts, 2021-2030.

Overview:

Cancer is one of the leading causes of death worldwide, accounting for an estimated 1.8 million mortalities in 2020, in the US alone. Moreover, according to the World Health Organization, the number of newly diagnosed cancer cases is anticipated to grow by 70%, worldwide, over the next 20 years. Till date, it has been established that conventional treatment options, which include chemotherapy, radiation therapy, and surgery, are limited when it comes to treating late-stage cancers. Immunotherapy, especially T cell-based products, has emerged as a viable and promising treatment option, having demonstrated the capability to selectively target and eliminate tumor cells. Over time, the approval and clinical success of several chimeric antigen receptor (CAR) transduced T-cell based immunotherapy candidates, have inspired numerous research groups across the world, to focus their efforts on this relatively novel class of anticancer therapies. In fact, CAR-T cell therapies are presently considered among the most promising therapeutics available to treat various types of hematological malignancies and solid tumors. In addition, T-cell based therapies featuring CAR constructs designed against pathogenic entities that are characteristic of a number of non-oncological indications, are also under investigation.

Currently, there are four approved CAR-T cell therapies, namely KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences) and BREYANZI® (Bristol Myers Squibb / Juno Therapeutics). Owing to advances in fundamental research on disease biology, a myriad of viable biological targets that can be drugged using CARs have been identified. Leveraging available data, industry stakeholders are actively strengthening their respective pipelines; there are more than 755 CAR-T cell-based product candidates that are presently being evaluated in clinical and preclinical trials. This upcoming class of biologics is also driven by the availability of several innovative technology platforms that enable genetic manipulation and cell therapy development, and lucrative capital investments from both public and private investors. With multiple therapeutic leads in the mid to late-stages of development (phase II and above) , and soon anticipated to enter the market, we are led to believe that the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.

Scope of the Report:

The "CAR-T Cell Therapies Market (3rd Edition) by Target Indications (Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Colorectal Cancer), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Global Forecast 2021-2030" report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of CAR-T cell therapies based on the type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved) , therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (acute lymphoblastic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, brain cancer, chronic lymphocytic leukemia, pancreatic cancer, liver cancer, lung cancer, stomach cancer, ovarian cancer, breast cancer, mesothelioma, colon cancer, Hodgkin lymphoma, sarcoma, bone cancer, melanoma, and others), key target antigen (CD19, BCMA, CD22, CD20, GD2, Meso, CD38, CD123, MUC1, CD30, HER2, GPC3, CD33, EGFR, EGFRvIII, PD-L1, PSMA and others) , source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others) , dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and seniors) , and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific.
  • Detailed profiles of marketed and mid to late stage clinical products (phase I/II or above) ; each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2x2 representation highlighting the KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers involved in the development of CAR-T cell therapies.
  • An analysis of the completed, ongoing, and planned clinical studies of various CAR-T cell therapies, based on trial registration year and geographical location of the clinical trial centers. In addition, we have provided a list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the focus areas of therapy developers (in terms of target disease indication), including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies, along with profiles of key technology providers, and a competitiveness analysis of different gene editing platforms (used for the development of CAR-T cell therapies) , based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates) , product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary CAR-T cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell based therapies that is likely to be marketed in the coming years.
  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030. The report also includes likely sales forecasts of CAR-T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR-T cell therapy market, wherein opportunity has been segmented across [A] target indications (non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma, hepatocellular carcinoma and colorectal cancer) , [B] target antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR) and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world) . In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • What are the prevalent R&D trends in CAR-T cell therapies domain?
  • What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
  • What are the various challenges being faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players in this market?
  • Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders / experts that can help in driving the development efforts?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What kind of contract manufacturing support is available for CAR-T cell therapies, across different regions?
  • What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved and commercialized in future?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T cell therapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of CAR-T cell therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell based therapies and the challenges associated with such therapies.

Chapter 4 provides insights on the popularity of CAR-T cell therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 features an assessment of the CAR-T cell therapies that are currently approved or in different stages of development. It features a detailed analysis of pipeline molecules with respect to the type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (acute lymphoblastic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia, brain cancer, chronic lymphocytic leukemia, pancreatic cancer, liver cancer, lung cancer, stomach cancer, ovarian cancer, breast cancer, mesothelioma, colon cancer, Hodgkin lymphoma, sarcoma, bone cancer, melanoma, and others), key target antigen (CD19, BCMA, CD22, CD20, GD2, Meso, CD38, CD123, MUC1, CD30, HER2, GPC3, CD33, EGFR, EGFRvIII, PD-L1, PSMA and others), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific.

Chapter 6 presents a collection of key insights derived from the study. It includes an insightful representation highlighting the most popular targets of CAR-T therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapies (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.

Chapter 7 presents an analysis of the clinical trials of CAR-T registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9 includes an overview of the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the CAR-T cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 10 provides a list of technology platforms that are either available in the market or under designed for the development of CAR-T cell therapies and a detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of CAR-T cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 11 features a analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 12 provides details on the investments and grants that have been awarded to players focused on the development of CAR-T cell therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 13 provides insights on cell therapy manufacturing, highlighting the current challenges in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 14 highlights our views on the various factors that must be taken into consideration while deciding the prices of CAR-T cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their CAR-T cell-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 15 features an elaborate discussion on the future commercial opportunity offered by CAR-T cell therapies. It provides an informed market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma, hepatocellular carcinoma and colorectal cancer), [B] target antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR) and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 16 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 17 includes brief company profiles of the leading players in the CAR-T cell therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to CAR-T cell therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 18 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 19 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Miguel Forte (Chief Operating Officer, TxCell), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Overview of Immunotherapy
  • 3.4. Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
      • 3.5.1.1. Active Immunotherapy
      • 3.5.1.2. Passive Immunotherapy
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
      • 3.5.3.1. Activation and Suppression Immunotherapy
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Oncolytic Virus Therapy
      • 3.5.4.5. Therapeutic Cancer Vaccines
      • 3.5.4.6. Cell-based Therapies
  • 3.6. T-Cell Immunotherapies
    • 3.6.1. Historical Evolution
    • 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
    • 3.6.3. Strategies Employed for the Redirection of T-Cells
    • 3.6.4. Manufacturing of Engineered T-Cells
    • 3.6.5. T-Cell Transduction and Transfection Methods
      • 3.6.5.1. Retroviral Vectors
      • 3.6.5.2. Lentiviral Vectors
      • 3.6.5.3. Non-viral Transfection Methods
  • 3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
    • 3.7.1. History of Development
    • 3.7.2. Anatomical Layout of CAR
      • 3.7.2.1. Ectodomain
      • 3.7.2.2. Transmembrane (TM) Domain
      • 3.7.2.3. Endodomain
    • 3.7.3. Development of CAR-T Cells
    • 3.7.4. Universal CAR-T Cells
    • 3.7.5. Route of Administration of CAR-T Cell Therapies
    • 3.7.6. Case Study: CD19 CAR-T Cell Therapies
      • 3.7.6.1. Other Important Biological Targets for CAR Development
    • 3.7.7. Challenges Associated with CAR-T Cell Therapies
      • 3.7.7.1. Competitive Risks
      • 3.7.7.2. Clinical Risks
      • 3.7.7.3. Regulatory Risks
      • 3.7.7.4. Commercial Risks

4. EMERGING TRENDS ON SOCIAL MEDIA

  • 4.1. Chapter Overview
  • 4.2. CAR-T Cell Therapies: Trends on Twitter
    • 4.2.1. Historical Trend in Volume of Tweets
    • 4.2.2. Trending Words / Phrases on Twitter
    • 4.2.3. Most Popular Drugs on Twitter
    • 4.2.4. Most Prolific Authors on Twitter
    • 4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. CAR-T Cell Therapies: Overall Market Landscape
    • 5.2.1. Analysis by Type of Developer
    • 5.2.2. Analysis by Phase of Development
    • 5.2.3. Analysis by Therapeutic Area
    • 5.2.4. Analysis by Popular Target Indications
    • 5.2.5. Analysis by Popular Target Antigens
    • 5.2.6. Analysis by Source of T-Cells
    • 5.2.7. Analysis by Route of Administration
    • 5.2.8. Analysis by Dose Frequency
    • 5.2.9. Analysis by Target Patient Segment
    • 5.2.10. Analysis by Type of Therapy
    • 5.2.11. Key Industry Players: Distribution by Number of Therapies in Pipeline
    • 5.2.12. Key Non-Industry Players: Distribution by Number of Therapies in Pipeline

6. KEY INSIGHTS

  • 6.1. Chapter Overview
  • 6.2. CAR-T Cell Therapies: Competitive Analysis by Popular Target Antigens
    • 6.2.1. Popular Targets Related to Hematological Malignancies
      • 6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
      • 6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
      • 6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
      • 6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies
    • 6.2.2. Popular Targets Related to Solid Tumors
      • 6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
      • 6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
      • 6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
      • 6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies
  • 6.3. CAR-T Cell Therapies: Key Opinion Leaders
    • 6.3.1. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
  • 6.4. CAR-T Cell Therapies: CAR Construct Analysis
    • 6.4.1. Analysis by Generation of CAR
    • 6.4.2. Analysis by Type of scFv Antibody
    • 6.4.3. Analysis by Type of Vector
    • 6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. CAR-T Cell Therapies: Clinical Trial Analysis
    • 7.2.1. Methodology
    • 7.2.2. Analysis by Trial Registration Year
    • 7.2.3. Geographical Analysis by Number of Registered Trials
    • 7.2.4. Case Study: CAR-T Cell Therapy Market in China
      • 7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES

  • 8.1. Chapter Overview
  • 8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
    • 8.2.1. Therapy Overview
      • 8.2.1.1. History of Development
    • 8.2.2. Current Status of Development
    • 8.2.3. Key Clinical Trial Results
    • 8.2.4. Dosage Regimen, Price and Manufacturing
  • 8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
    • 8.3.1. Therapy Overview
      • 8.3.1.1. History of Development
    • 8.3.2. Current Status of Development
    • 8.3.3. Key Clinical Trial Results
    • 8.3.4. Dosage Regimen, Price and Manufacturing
  • 8.4. TECARTUS® / Brexucabtagene Autoleucel (Kite Pharma)
    • 8.4.1. Therapy Overview
    • 8.4.2. Current Status of Development
    • 8.4.3. Key Clinical Trial Results
    • 8.4.4. Dosage Regimen, Price and Manufacturing
  • 8.5. JCAR (Juno Therapeutics (a Bristol Myers Squibb Company))
    • 8.5.1. Therapy Overview
      • 8.5.1.1. CAR-T Design
    • 8.5.2. Current Status of Development
    • 8.5.3. Key Clinical Results
      • 8.5.3.1. JCAR014
      • 8.5.3.2. JCAR017
      • 8.5.3.3. JCAR018
      • 8.5.3.4. JCARH125
    • 8.5.4. Dosage Regimen and Manufacturing
  • 8.6. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol-Myers Squibb)
    • 8.6.1. Therapy Overview
    • 8.6.2. Current Status of Development
    • 8.6.3. Key Clinical Trial Results
    • 8.6.4. Dosage Regimen and Manufacturing
  • 8.7. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Nanjing Legend Biotech / Janssen Biotech)
    • 8.7.1. Therapy Overview
    • 8.7.2. Current Status of Development
    • 8.7.3. Key Clinical Trial Results
    • 8.7.4. Dosage Regimen and Manufacturing
  • 8.8. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
    • 8.8.1. Therapy Overview
    • 8.8.2. Current Status of Development
    • 8.8.3. Key Clinical Trial Results
    • 8.8.4. Dosage Regimen and Manufacturing
  • 8.9. Next Generation CAR-T Cell therapies (Autolus)
    • 8.9.1. Therapy Overview
    • 8.9.2. Current Status of Development
    • 8.9.3. Key Clinical Trial Results
      • 8.9.3.1. AUTO1
      • 8.9.3.2. AUTO3
    • 8.9.4. Dosage Regimen and Manufacturing
  • 8.10. CAR-T Cell Therapies (Sinobioway Cell Therapy)
    • 8.10.1. Therapy Overview
    • 8.10.2. Current Status of Development
    • 8.10.3. Dosage Regimen and Manufacturing

9. KEY THERAPEUTIC AREAS FOR CAR-T CELL THERAPIES

  • 9.1. Chapter Overview
  • 9.2. Hematological Malignancies
    • 9.2.1. Leukemia and Lymphoma
      • 9.2.1.1. Leukemia: Introduction and Epidemiology
        • 9.2.1.1.1. Acute Myeloid Leukemia (AML)
        • 9.2.1.1.2. Chronic Myeloid Leukemia (CML)
        • 9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
        • 9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
      • 9.2.1.2. Lymphoma: Introduction and Epidemiology
      • 9.2.1.3. Current Treatment Landscape
        • 9.2.1.3.1. Targeted Therapies
      • 9.2.1.4. CAR-T Cell Therapies and Affiliated Research Landscape
        • 9.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
    • 9.2.2. Multiple Myeloma
      • 9.2.2.1. Introduction and Epidemiology
      • 9.2.2.2. Current Treatment Landscape
      • 9.2.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
  • 9.3. Solid Tumors
    • 9.3.1. Metastatic Melanoma
      • 9.3.1.1. Introduction and Epidemiology
      • 9.3.1.2. Current Treatment Landscape
      • 9.3.1.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.2. Lung Cancer
      • 9.3.2.1. Introduction and Epidemiology
      • 9.3.2.2. Current Treatment Landscape
      • 9.3.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.3. Pancreatic Cancer
      • 9.3.3.1. Introduction and Epidemiology
      • 9.3.3.2. Current Treatment Landscape
      • 9.3.3.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.4. Liver Cancer
      • 9.3.4.1. Introduction and Epidemiology
      • 9.3.4.1. Current Treatment Landscape
      • 9.3.4.2. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.5. Breast Cancer
      • 9.3.5.1. Introduction and Epidemiology
      • 9.3.5.2. Current Treatment Landscape
      • 9.3.5.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.6. Ovarian Cancer
      • 9.3.6.1. Introduction and Epidemiology
      • 9.3.6.2. Current Treatment Landscape
      • 9.3.6.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.7. Bladder Cancer
      • 9.3.7.1. Introduction and Epidemiology
      • 9.3.7.2. Current Treatment Landscape
      • 9.3.7.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.8. Kidney Cancer
      • 9.3.8.1. Introduction and Epidemiology
      • 9.3.8.2. Current Treatment Landscape
      • 9.3.8.3. CAR-T Cell Therapies and Affiliated Research Landscape

10. EMERGING TECHNOLOGIES

  • 10.1. Chapter Overview
  • 10.2. Genome Editing Technologies
    • 10.2.1. Applications of Genome Editing Technologies
    • 10.2.2. Emerging Technology Platforms for CAR-T Cell Therapy Development and Production
      • 10.2.2.1. CRISPR / Cas9 System
        • 10.2.2.1.1. Key Components and Function
        • 10.2.2.1.2. Mechanism of Action
        • 10.2.2.1.3. Targeting Efficiency and Challenges
        • 10.2.2.1.4. Next-GEN CRISPR Technology
        • 10.2.2.1.5. Technology Providers
          • 10.2.2.1.5.1. Editas Medicine
          • 10.2.2.1.5.2. Intellia Therapeutics
          • 10.2.2.1.5.3. CRISPR Therapeutics
          • 10.2.2.1.5.4. Beam Therapeutics
          • 10.2.2.1.5.5. Gracell Biotechnologies
      • 10.2.2.2. TALENs
        • 10.2.2.2.1. Key Components and Function
        • 10.2.2.2.2. Mechanism of Action
        • 10.2.2.2.3. Advantages and Challenges
        • 10.2.2.2.4. Technology Providers
          • 10.2.2.2.4.1. Cellectis
          • 10.2.2.2.4.2. Editas Medicine
      • 10.2.2.3. megaTAL
        • 10.2.2.3.1. Technology Providers
          • 10.2.2.3.1.1. bluebird bio
      • 10.2.2.4. Zinc Finger Nuclease
        • 10.2.2.4.1. Technology Providers
          • 10.2.2.4.1.1. Sangamo Therapeutics
    • 10.2.3. Competitive Analysis: Gene Editing Platforms
  • 10.3. Designing CAR-T Cell Therapies with Improved Characteristics
    • 10.3.1. Technologies for Targeting Multiple Cancers
      • 10.3.1.1. Antibody Coupled T-Cell Receptor
        • 10.3.1.1.1. Unum Therapeutics
      • 10.3.1.2. NKR-T Platform
        • 10.3.1.2.1. Celyad Oncology
        • 10.3.1.2.2. Glycostem
    • 10.3.2. Technologies for Improved Safety
      • 10.3.2.1. Armored CAR and EGFRt Technology
        • 10.3.2.1.1. Juno Therapeutics
      • 10.3.2.2. RheoSwitch Therapeutic System
        • 10.3.2.2.1. Intrexon
      • 10.3.2.3. Inducible Caspase 9 Safety Switch
        • 10.3.2.3.1. Bellicum Pharmaceuticals
          • 10.3.2.3.1.1. CaspaCIDe Technology
          • 10.3.2.3.1.2. CIDeCAR Technology
          • 10.3.2.3.1.3. GoCAR-T Technology
      • 10.3.2.3. On-Off Switch, Multiple Companies
        • 10.3.2.3.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
        • 10.3.2.3.2. On-Off Switch (Theravectys)
      • 10.3.2.4. Other Technologies to Improve CAR-T Safety
    • 10.3.3. Allogeneic Technologies
      • 10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
      • 10.3.3.2. Allogeneic Platform (Celyad)
      • 10.3.3.3. Allogeneic Platform (Cellectis)

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. CAR-T Cell Therapy Market: List of Partnerships and Collaborations
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Most Popular Products
    • 11.3.4. Most Active Industry Players: Analysis by Number of Partnerships
    • 11.3.5. Most Active Non-Industry Players: Analysis by Number of Partnerships
    • 11.3.6. Most Active Contract Manufacturers: Analysis by Number of Manufacturing
    • 11.3.7. Regional Analysis
    • 11.3.8. Intercontinental and Intracontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Types of Funding
  • 12.3. CAR-T Cell Therapy Market: Funding and Investment Analysis
    • 12.3.1. Analysis by Year of Investment
    • 12.3.2. Analysis by Amount Invested
    • 12.3.3. Analysis by Type of Funding
    • 12.3.4. Most Active Players: Analysis by Number of Funding Instances
    • 12.3.5. Analysis by Type of Investor
    • 12.3.6. Most Active Investors: Analysis by Number of Funding Instances
    • 12.3.7. Regional Analysis by Amount Invested

13. CASE STUDY: CELL THERAPY MANUFACTURING

  • 13.1. Chapter Overview
  • 13.2. Overview of Cell Therapy Manufacturing
  • 13.3. Cell Therapy Manufacturing Models
    • 13.3.1. Centralized Manufacturing Model
    • 13.3.2. Decentralized Manufacturing Model
  • 13.4. Scalability of Cell Therapy Manufacturing Processes
    • 13.4.1. Scale-Up
    • 13.4.2. Scale-Out
  • 13.5. Types of Cell Therapy Manufacturers
  • 13.6. Key Challenges Associated with Manufacturing of Cell Therapies
  • 13.7. Important Factors for Cell Therapy Manufacturing
    • 13.7.1. Characterization
    • 13.7.2. Cost of Goods
  • 13.8. Automation of Cell Therapy Manufacturing Process
  • 13.9. Cell Therapy Manufacturing Supply Chain
  • 13.10. Companies with In-House Capabilities
  • 13.11. Contract Manufacturers
  • 13.12. Regulatory Landscape

14. COST PRICE ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Factors Contributing to the High Price of Cell / Gene Therapies
  • 14.3. Pricing Models for CAR-T Cell Therapies
    • 14.3.1. Based on Associated Costs
    • 14.3.2. Based on Availability of Competing Products
    • 14.3.3. Based on Target Patient Segment
    • 14.3.4. Based on the Opinions of Industry Experts
  • 14.4. Reimbursement-related Considerations for CAR-T Cell Therapies
    • 14.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Scope and Limitations
  • 15.3. Key Assumptions and Forecast Methodology
  • 15.4. Overall CAR-T Cell Therapy Market, 2021-2030
    • 15.4.1. CAR-T Cell Therapies Market: Distribution by Target Indication
    • 15.4.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
    • 15.4.3. CAR-T Cell Therapies Market: Distribution by Key Players
    • 15.4.4. CAR-T Cell Therapies Market: Distribution by Geography
    • 15.4.5. Product Wise Sales Forecast
      • 15.4.5.1. KYMRIAH® (Novartis)
        • 15.4.5.1.1. Target Patient Population
        • 15.4.5.1.2. Sales Forecast (USD Million)
        • 15.4.5.1.3. Net Present Value (USD Million)
        • 15.4.5.1.4. Value Creation Analysis
      • 15.4.5.2. YESCARTA® (Gilead Sciences)
        • 15.4.5.2.1. Target Patient Population
        • 15.4.5.2.2. Sales Forecast (USD Million)
        • 15.4.5.2.3. Net Present Value (USD Million)
        • 15.4.5.2.4. Value Creation Analysis
      • 15.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
        • 15.4.5.3.1. Target Patient Population
        • 15.4.5.3.2. Sales Forecast (USD Million)
        • 15.4.5.3.3. Net Present Value (USD Million)
        • 15.4.5.3.4. Value Creation Analysis
      • 15.4.5.4. BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics)
        • 15.4.5.4.1. Target Patient Population
        • 15.4.5.4.2. Sales Forecast (USD Million)
        • 15.4.5.4.3. Net Present Value (USD Million)
        • 15.4.5.4.4. Value Creation Analysis
      • 15.4.5.5. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb)
        • 15.4.5.5.1. Target Patient Population
        • 15.4.5.5.2. Sales Forecast (USD Million)
        • 15.4.5.5.3. Net Present Value (USD Million)
        • 15.4.5.5.4. Value Creation Analysis
      • 15.4.5.6. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
        • 15.4.5.6.1. Target Patient Population
        • 15.4.5.6.2. Sales Forecast (USD Million)
        • 15.4.5.6.3. Net Present Value (USD Million)
        • 15.4.5.6.4. Value Creation Analysis
      • 15.4.5.7. MB-CART19.1 (Miltenyi Biotec)
        • 15.4.5.7.1. Target Patient Population
        • 15.4.5.7.2. Sales Forecast (USD Million)
        • 15.4.5.7.3. Net Present Value (USD Million)
        • 15.4.5.7.4. Value Creation Analysis
      • 15.4.5.8. Descartes-11 (Cartesian Therapeutics)
        • 15.4.5.8.1. Target Patient Population
        • 15.4.5.8.2. Sales Forecast (USD Million)
        • 15.4.5.8.3. Net Present Value (USD Million)
        • 15.4.5.8.4. Value Creation Analysis
      • 15.4.5.9. CD19 CAR-T (Sinobioway Cell Therapy)
        • 15.4.5.9.1. Target Patient Population
        • 15.4.5.9.2. Sales Forecast (USD Million)
        • 15.4.5.9.3. Net Present Value (USD Million)
        • 15.4.5.9.4. Value Creation Analysis
      • 15.4.5.10. AUTO1 (Autolus)
        • 15.4.5.10.1. Target Patient Population
        • 15.4.5.10.2. Sales Forecast (USD Million)
        • 15.4.5.10.3. Net Present Value (USD Million)
        • 15.4.5.10.4. Value Creation Analysis
      • 15.4.5.11. AUTO3 (Autolus)
        • 15.4.5.11.1. Target Patient Population
        • 15.4.5.11.2. Sales Forecast (USD Million)
        • 15.4.5.11.3. Net Present Value (USD Million)
        • 15.4.5.11.4. Value Creation Analysis
      • 15.4.5.12. GPC3 CAR-T (Shanghai GeneChem)
        • 15.4.5.12.1. Target Patient Population
        • 15.4.5.12.2. Sales Forecast (USD Million)
        • 15.4.5.12.3. Net Present Value (USD Million)
        • 15.4.5.12.4. Value Creation Analysis
      • 15.4.5.13. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
        • 15.4.5.13.1. Target Patient Population
        • 15.4.5.13.2. Sales Forecast (USD Million)
        • 15.4.5.13.3. Net Present Value (USD Million)
        • 15.4.5.13.4. Value Creation Analysis
      • 15.4.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
        • 15.4.5.14.1. Target Patient Population
        • 15.4.5.14.2. Sales Forecast (USD Million)
        • 15.4.5.14.3. Net Present Value (USD Million)
        • 15.4.5.14.4. Value Creation Analysis
      • 15.4.5.15. CD19 CAR-T (Shanghai Bioray Laboratory)
        • 15.4.5.15.1. Target Patient Population
        • 15.4.5.15.2. Sales Forecast (USD Million)
        • 15.4.5.15.3. Net Present Value (USD Million)
        • 15.4.5.15.4. Value Creation Analysis
      • 15.4.5.16. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
        • 15.4.5.16.1. Target Patient Population
        • 15.4.5.16.2. Sales Forecast (USD Million)
        • 15.4.5.16.3. Net Present Value (USD Million)
        • 15.4.5.16.4. Value Creation Analysis
      • 15.4.5.17. PCAR-019 (PersonGen BioTherapeutics)
        • 15.4.5.17.1. Target Patient Population
        • 15.4.5.17.2. Sales Forecast (USD Million)
        • 15.4.5.17.3. Net Present Value (USD Million)
        • 15.4.5.17.4. Value Creation Analysis
      • 15.4.5.18. TBI-1501 (Takara Bio)
        • 15.4.5.18.1. Target Patient Population
        • 15.4.5.18.2. Sales Forecast (USD Million)
        • 15.4.5.18.3. Net Present Value (USD Million)
        • 15.4.5.18.4. Value Creation Analysis
      • 15.4.5.19. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
        • 15.4.5.19.1. Target Population
        • 15.4.5.19.2. Sales Forecast (USD Million)
        • 15.4.5.19.3. Net Present Value (USD Million)
        • 15.4.5.19.4. Value Creation Analysis
      • 15.4.5.20. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
        • 15.4.5.20.1. Target Patient Population
        • 15.4.5.20.2. Sales Forecast (USD Million)
        • 15.4.5.20.3. Net Present Value (USD Million)
        • 15.4.5.20.4. Value Creation Analysis
      • 15.4.5.21. BinD19 (Shenzhen BinDeBio)
        • 15.4.5.21.1. Target Patient Population
        • 15.4.5.21.2. Sales Forecast (USD Million)
        • 15.4.5.21.3. Net Present Value (USD Million)
        • 15.4.5.21.4. Value Creation Analysis
      • 15.4.5.22. CARCIK-CD19 (Formula Pharmaceuticals)
        • 15.4.5.22.1. Target Patient Population
        • 15.4.5.22.2. Sales Forecast (USD Million)
        • 15.4.5.22.3. Net Present Value (USD Million)
        • 15.4.5.22.4. Value Creation Analysis
      • 15.4.5.23. EGFR CAR-T Cell Therapy (The Beijing Pregene Science and Technology)
        • 15.4.5.23.1. Target Patient Population
        • 15.4.5.23.2. Sales Forecast (USD Million)
        • 15.4.5.23.3. Net Present Value (USD Million)
        • 15.4.5.23.4. Value Creation Analysis
      • 15.4.5.24. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
        • 15.4.5.24.1. Target Patient Population
        • 15.4.5.24.2. Sales Forecast (USD Million)
        • 15.4.5.24.3. Net Present Value (USD Million)
        • 15.4.5.24.4. Value Creation Analysis
      • 15.4.5.25. PBCAR269A (Precision BioSciences and Servier)
        • 15.4.5.25.1. Target Patient Population
        • 15.4.5.25.2. Sales Forecast (USD Million)
        • 15.4.5.25.3. Net Present Value (USD Million)
        • 15.4.5.25.4. Value Creation Analysis
      • 15.4.5.26. CD123 CAR-T cell Therapy (Chongqing Precision Biotechnology)
        • 15.4.5.26.1. Target Patient Population
        • 15.4.5.26.2. Sales Forecast (USD Million)
        • 15.4.5.26.3. Net Present Value (USD Million)
        • 15.4.5.26.4. Value Creation Analysis
      • 15.4.5.27. BCMA CAR-T (Chongqing Precision Biotech)
        • 15.4.5.27.1. Target Patient Population
        • 15.4.5.27.2. Sales Forecast (USD Million)
        • 15.4.5.27.3. Net Present Value (USD Million)
        • 15.4.5.27.4. Value Creation Analysis
      • 15.4.5.28. P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine)
        • 15.4.5.28.1. Target Patient Population
        • 15.4.5.28.2. Sales Forecast (USD Million)
        • 15.4.5.28.3. Net Present Value (USD Million)
        • 15.4.5.28.4. Value Creation Analysis

16. PROMOTIONAL ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Channels Used for Promotional Campaigns
  • 16.3. Summary of Product Website Analysis
  • 16.4. Summary of Patient Support Services and Informative Downloads
  • 16.5. KYMRIAH®: Promotional Analysis
    • 16.5.1. Drug Overview
    • 16.5.2. Product Website Analysis
      • 16.5.2.1. Messages for Healthcare Professionals
      • 16.5.2.2. Messages for Patients
    • 16.5.3. Patient Support Services and Informative Downloads
    • 16.5.4. Other Promotional Activities
      • 16.5.4.1. Presence in Conferences
  • 16.6. YESCARTA®: Promotional Analysis
    • 16.6.1. Drug Overview
    • 16.6.2. Product Website Analysis
      • 16.6.2.1. Messages for Healthcare Professionals
      • 16.6.2.3. Messages for Patients
    • 16.6.3. Patient Support Services and Informative Downloads
    • 16.6.4. Other Promotional Activities
      • 16.6.4.1. Presence in Conferences

17. COMPANY PROFILES

  • 17.1. Chapter Overview
  • 17.2. Autolus
  • 17.3. bluebird bio
  • 17.4. CARsgen Therapeutics
  • 17.5. Celgene (A Bristol Myers Squibb Company)
  • 17.6. Cellectis
  • 17.7. Cellular Biomedicine Group
  • 17.8. Innovative Cellular Therapeutics
  • 17.9. Kite Pharma (A Gilead Sciences Company)
  • 17.10. Kuur Therapeutics
  • 17.11. Noile-Immune Biotech
  • 17.12. Novartis
  • 17.13. Shanghai Genechem
  • 17.14. Sinobioway Cell Therapy
  • 17.15. Takara Bio
  • 17.16. Ziopharm Oncology

18. CONCLUDING REMARKS

  • 18.1. Chapter Overview

19. EXECUTIVE INSIGHTS

  • 19.1. Chapter Overview
  • 19.2. Cell Therapies
    • 19.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
  • 19.3. Celyad
    • 19.3.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
  • 19.4. Changhai Hospital
    • 19.4.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
  • 19.5. Glycostem Therapeutics
    • 19.5.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
  • 19.6. Gracell Biotechnologies
    • 19.6.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
  • 19.7. Kite Pharma
    • 19.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
  • 19.8. Theravectys
    • 19.8.1. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
  • 19.9. TxCell
    • 19.9.1. Interview Transcript: Miguel Forte, Chief Operating Officer
  • 19.10. University of Colorado
    • 19.10.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
  • 19.11. Waisman Biomanufacturing
    • 19.11.1. Interview Transcript: Brian Dattilo, Manager of Business Development

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Pillars of Cancer Therapy
  • Figure 3.2 Differences between Active and Passive Immunotherapies
  • Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
  • Figure 3.4 Strategies Employed for the Redirection of T-Cells
  • Figure 3.5 T-Cell Manufacturing: General Procedure
  • Figure 3.6 Historical Development of CAR-T cells
  • Figure 3.7 Structure of Chimeric Antigen Receptor
  • Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
  • Figure 3.9 CAR-T Cell Therapies: Development Process
  • Figure 3.10 Challenges Associated with CAR-T Cell Therapies
  • Figure 4.1 Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
  • Figure 4.2 Social Media Analysis: Trending Words / Phrases on Twitter
  • Figure 4.3 Social Media Analysis: Most Popular Drug Candidates on Twitter
  • Figure 4.4 Social Media Analysis: Most Prolific Authors on Twitter
  • Figure 4.5 Average Number of Likes, Re-tweets and Comments Related to CAR-T Cell Therapies
  • Figure 4.6 Social Media Analysis: Most Popular Indications and Target Antigen
  • Figure 5.1 CAR-T Cell Therapies: Distribution by Type of Developer
  • Figure 5.2 CAR-T Cell Therapies: Distribution by Phase of Development
  • Figure 5.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
  • Figure 5.4 CAR-T Cell Therapies: Distribution by Popular Target Indications
  • Figure 5.5 CAR-T Cell Therapies: Distribution by Popular Target Antigens
  • Figure 5.6 CAR-T Cell Therapies: Distribution by Source of T-Cells
  • Figure 5.7 CAR-T Cell Therapies: Distribution by Route of Administration
  • Figure 5.8 CAR-T Cell Therapies: Distribution by Dose Frequency
  • Figure 5.9 CAR-T Cell Therapies: Distribution by Target Patient Segment
  • Figure 5.10 CAR-T Cell Therapies: Distribution by Type of Therapy
  • Figure 5.11 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
  • Figure 5.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
  • Figure 5.13 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
  • Figure 5.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
  • Figure 6.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
  • Figure 6.2 CAR-T Cell Therapies: Popular Targets in Solid Tumor
  • Figure 6.3 CAR-T Cell Therapies: Geographical Distribution of Key Opinion Leaders
  • Figure 6.4 CAR-T Cell Therapies: Prominent Key Opinion Leaders
  • Figure 6.5 CAR-Construction: Analysis by Generation of CAR-T Therapies
  • Figure 6.6 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
  • Figure 6.7 CAR-Construction: Analysis by Type of Vector
  • Figure 6.8 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
  • Figure 7.1 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
  • Figure 7.2 CAR-T Cell Therapy Clinical Trials: Distribution by Year of Registration and Geography (Pre-2016 and 2016-2019)
  • Figure 8.1 Manufacturing of CD19 CAR-T Cells: Process Comparison
  • Figure 9.1 Leukemia: Classification
  • Figure 9.2 Leukemia: Global Epidemiological Distribution
  • Figure 9.3 Lymphoma: Global Epidemiological Distribution
  • Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
  • Figure 9.5 Melanoma: Global Epidemiological Distribution
  • Figure 9.6 Lung Cancer: Classification
  • Figure 9.7 Lung Cancer: Global Epidemiological Distribution
  • Figure 9.8 Pancreatic Cancer: Global Epidemiological Distribution
  • Figure 9.9 Liver Cancer: Global Epidemiological Distribution
  • Figure 9.10 Breast Cancer: Global Epidemiological Distribution
  • Figure 9.11 Ovarian Cancer: Global Epidemiological Distribution
  • Figure 9.12 Bladder Cancer: Global Epidemiological Distribution
  • Figure 9.13 Kidney Cancer: Global Epidemiological Distribution
  • Figure 10.1 Genome Editing Technologies: Applications
  • Figure 10.2 Genome Editing: Emerging Technology Platforms Used in CAR-T Cell Therapies
  • Figure 10.3 Competitiveness Analysis: Gene Editing Platforms
  • Figure 10.4 CAR-T Cell Therapies: Key Technologies to Enhance Features / Characteristics
  • Figure 10.5 Cellectis: Properties of Enhanced T-Cell Platform
  • Figure 10.6 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
  • Figure 11.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
  • Figure 11.2 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2013-2020
  • Figure 11.3 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
  • Figure 11.5 Partnerships and Collaborations: Distribution by Individual Products
  • Figure 11.6 Partnerships and Collaborations: Most Active Industry Players
  • Figure 11.7 Partnerships and Collaborations: Most Active Non-Industry Players
  • Figure 11.8 Partnerships and Collaborations: Most Active Contract Manufacturers
  • Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
  • Figure 11.10 Partnerships and Collaborations: Regional Distribution
  • Figure 11.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre 2013-2020 (till October)
  • Figure 12.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre 2013-2020 (USD Million)
  • Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 12.5 Most Active Players: Distribution by Number of Funding Instances
  • Figure 12.6 Funding and Investment: Distribution by Types of Investor
  • Figure 12.7 Most Active Players: Distribution by Number of Instances
  • Figure 12.8 Funding and Investment Analysis: Distribution by Geography
  • Figure 12.9 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
  • Figure 13.1 Steps in Cell Therapy Manufacturing
  • Figure 13.2 Centralized Manufacturing: Process Model
  • Figure 13.3 Decentralized Manufacturing: Process Model
  • Figure 13.4 Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 13.5 Cell Therapy Manufacturing: Challenges and Drivers
  • Figure 13.6 Cell Therapies: Potency as Critical Quality Attribute
  • Figure 13.7 Cell Therapy Manufacturing: Supply Chain Model
  • Figure 13.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
  • Figure 14.1 Targeted Therapies: Pricing Model Based on Patient Segment
  • Figure 15.1 Overall CAR-T Cell Therapies Market, 2021-2030 (USD Billion)
  • Figure 15.2 CAR-T Cell Therapies Market: Distribution by Target Indication (USD Billion)
  • Figure 15.3 CAR-T Cell Therapies Market: Distribution by Target Antigen (USD Billion)
  • Figure 15.4 CAR-T Cell Therapies Market: Key Players (USD Billion)
  • Figure 15.5 CAR-T Cell Therapies Market: Distribution by Target Geography (USD Billion)
  • Figure 15.6 KYMRIAH® (Novartis): Current Status of Development
  • Figure 15.7 KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
  • Figure 15.8 YESCARTA® (Gilead Sciences): Current Status of Development
  • Figure 15.9 YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
  • Figure 15.10 TECARTUS® (Gilead Sciences): Current Status of Development
  • Figure 15.11 TECARTUS®: (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
  • Figure 15.12 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Current Status of Development
  • Figure 15.13 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 15.14 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Current Statusof Development
  • Figure 15.15 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, till 2030 (USD Million)
  • Figure 15.16 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Current Status of Development
  • Figure 15.17 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
  • Figure 15.18 MB-CART19.1 (Miltenyi Biotec): Current Status of Development
  • Figure 15.19 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
  • Figure 15.20 Descartes-11 (Cartesian Therapeutics): Current Status of Development
  • Figure 15.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 15.22 CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
  • Figure 15.23 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
  • Figure 15.24 AUTO1 (Autolus): Current Status of Development
  • Figure 15.25 AUTO1 (Autolus) Sales Forecast, till 2030 (USD Million)
  • Figure 15.26 AUTO3 (Autolus): Current Status of Development
  • Figure 15.27 AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
  • Figure 15.28 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
  • Figure 15.29 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
  • Figure 15.30 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
  • Figure 15.31 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030(USD Million)
  • Figure 15.32 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status ofDevelopment
  • Figure 15.33 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
  • Figure 15.34 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
  • Figure 15.35 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
  • Figure 15.36 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
  • Figure 15.37 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, Sales Forecast, till 2030 (USD Million)
  • Figure 15.38 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
  • Figure 15.39 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 15.40 TBI-1501 (Takara Bio): Current Status of Development
  • Figure 15.41 TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
  • Figure 15.42 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
  • Figure 15.43 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 15.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
  • Figure 15.45 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
  • Figure 15.46 BinD19 (Shenzhen BinDeBio): Current Status of Development
  • Figure 15.47 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
  • Figure 15.48 CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
  • Figure 15.49 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
  • Figure 15.50 EGFR CAR-T (The Beijing Pregene Science and Technology): Current Status of Development
  • Figure 15.51 EGFR CAR-T (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 15.52 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
  • Figure 15.53 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 15.54 PBCAR269A (Precision BioSciences and Servier): Current Status of Development
  • Figure 15.55 PBCAR269A (Precision BioSciences and Servier) Sales Forecast, till 2030 (USD Million)
  • Figure 15.56 CD123 CAR-T cells (Chongqing Precision Biotechnology): Current Status of Development
  • Figure 15.57 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2030 (USD Million)
  • Figure 15.58 BCMA CAR-T (Chongqing Precision Biotech): Current Status of Development
  • Figure 15.59 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2030 (USD Million)
  • Figure 15.60 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Current Status of Development
  • Figure 15.61 P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine) Sales Forecast, till 2030 (USD Million)
  • Figure 16.1 Channels Used for Promotional Campaigns
  • Figure 16.2 Promotional / Marketing Strategy: Product Website Analysis
  • Figure 16.3 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
  • Figure 16.4 Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
  • Figure 16.5 Product Website Analysis: KYMRIAH®, Messages for Patients
  • Figure 16.6 Product Website Analysis: KYMRIAH®, Patient Support Program
  • Figure 16.7 KYMRIAH®, Presence in Conferences
  • Figure 16.8 Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
  • Figure 16.9 Product Website Analysis: YESCARTA®, Messages for Patients
  • Figure 16.10 Product Website Analysis: YESCARTA®, Kite Konnect
  • Figure 16.11 Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
  • Figure 16.12 YESCARTA®, Presence in Conferences
  • Figure 18.1 Concluding Remarks: Overall Market Landscape
  • Figure 18.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 18.3 Concluding Remarks: Partnerships & Collaborations and Funding and Investment Analysis
  • Figure 18.4 Concluding Remarks: Market Forecast

List Of Tables

  • Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
  • Table 3.2 FDA Approved Antibody based Cancer Therapeutics
  • Table 3.3 Key Characteristics of CAR-T Cells
  • Table 3.4 Comparison of First and Second-Generation CAR-Ts
  • Table 3.5 CD19 CAR-T Cells: Preclinical Results
  • Table 3.6 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
  • Table 5.1 CAR-T Cell Therapies: Clinical Pipeline
  • Table 5.2 CAR-T Cell Therapies: Preclinical Pipeline
  • Table 6.1 CD19 CAR-T Cell Therapies: Competitive Landscape
  • Table 6.2 CD19 CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.3 BCMA CAR-T Cell Therapies: Competitive Landscape
  • Table 6.4 BCMA CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.5 Meso CAR-T Cell Therapies: Competitive Landscape
  • Table 6.6 Meso CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.7 GD2 CAR-T Cell Therapies: Competitive Landscape
  • Table 6.8 GD2 CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.9 CAR-T Cell Therapies: Principle Investigators
  • Table 6.10 CAR-T Therapies: Information on Constructs of Clinical Candidates
  • Table 7.1 CAR-T Cell Therapies: List of Clinical Trials
  • Table 7.2 Advanced Phase CAR-T Cell Therapies in China
  • Table 8.1 KYMRIAH®: Clinical Studies
  • Table 8.2 KYMRIAH®: Clinical Trial Endpoints (ALL)
  • Table 8.3 KYMRIAH®: Clinical Trial Endpoints (CLL / NHL / FL / MCL / CNSL)
  • Table 8.4 YESCARTA®: Clinical Studies
  • Table 8.5 YESCARTA®: Clinical Trial Endpoints
  • Table 8.6 TECARTUS® / Brexucabtagene Autoleucel: Clinical Studies
  • Table 8.7 TECARTUS® / Brexucabtagene Autoleucel: Clinical Trial Endpoints
  • Table 8.8 JCAR Series: Molecules in Clinical Phase of Development
  • Table 8.9 JCAR: CAR-T Design
  • Table 8.10 JCAR014: Clinical Studies
  • Table 8.11 JCAR017: Clinical Studies
  • Table 8.12 JCAR018: Clinical Studies
  • Table 8.13 JCAR020: Clinical Studies
  • Table 8.14 JCAR023: Clinical Studies
  • Table 8.15 JCAR024: Clinical Studies
  • Table 8.16 JCARH125: Clinical Studies
  • Table 8.17 JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
  • Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
  • Table 8.19 JCAR: Dosage Regimen
  • Table 8.20 Idecabtagene Vicleucel / bb2121: Clinical Studies
  • Table 8.21 Idecabtagene Vicleucel / bb2121: Clinical Trial Endpoints
  • Table 8.22 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Studies
  • Table 8.23 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Trial Endpoints
  • Table 8.24 TBI-1501: Clinical Studies
  • Table 8.25 TBI-1501: Clinical Trial Endpoints
  • Table 8.26 TBI-1501: Dosage Regimen
  • Table 8.27 AUTO1: Clinical Studies
  • Table 8.28 AUTO3: Clinical Studies
  • Table 8.29 AUTO4: Clinical Studies
  • Table 8.30 Autolus's Next Generation CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 8.31 Sinobioway Cell Therapy's CD19 CAR-T Therapy: Clinical Studies
  • Table 8.32 Sinobioway Cell Therapy's EPCAM CAR-T Therapy: Clinical Studies
  • Table 8.33 Sinobioway Cell Therapy's Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 8.34 Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
  • Table 9.1 Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
  • Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
  • Table 9.4 CAR-T Cell Therapies: Targets under Investigation for Leukemia
  • Table 9.5 CAR-T Cell Therapies: Targets under Investigation for Lymphoma
  • Table 9.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
  • Table 9.7 CAR-T Cell Therapies: Targets under Investigation for Multiple Myeloma
  • Table 9.8 Melanoma: List of Marketed Targeted Therapeutics
  • Table 9.9 CAR-T Cell Therapies: Targets under Investigation for Melanoma
  • Table 9.10 Lung Cancer: List of Marketed Targeted Therapeutics
  • Table 9.11 CAR-T Cell Therapies: Targets under Investigation for Lung Cancer
  • Table 9.12 Pancreatic Cancer: List of Marketed Targeted Therapeutics
  • Table 9.13 CAR-T Cell Therapies: Targets under Investigation for Pancreatic Cancer
  • Table 9.14 Liver Cancer: List of Marketed Targeted Therapeutics
  • Table 9.15 CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
  • Table 9.16 Breast Cancer: List of Marketed Targeted Therapeutics
  • Table 9.17 CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
  • Table 9.18 Ovarian Cancer: List of Marketed Targeted Therapeutics
  • Table 9.19 CAR-T Cell Therapies: Targets under Investigation for Ovarian Cancer
  • Table 9.20 Bladder Cancer: List of Marketed Targeted Therapeutics
  • Table 9.21 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
  • Table 10.1 Editas Medicine: CRISPR / Cas9 Technology, Research Publications
  • Table 10.2 Editas Medicine: Funding Instances
  • Table 10.3 Editas Medicine: Partnerships & Collaborations
  • Table 10.4 Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
  • Table 10.5 Intellia Therapeutics: Funding Instances
  • Table 10.6 Intellia Therapeutics: Collaborations
  • Table 10.7 CRISPR Therapeutics: CRISPR / Cas9 Technology, Research Publications
  • Table 10.8 CRISPR Therapeutics: Funding Instances
  • Table 10.9 CRISPR Therapeutics: Partnerships & Collaborations
  • Table 10.10 Beam Therapeutics: Funding Instances
  • Table 10.11 Beam Therapeutics: Collaborations
  • Table 10.12 Gracell Biotechnologies: Funding Instances
  • Table 10.13 Cellectis: Funding Instances
  • Table 10.14 Cellectis: Partnerships & Collaborations
  • Table 10.15 bluebird bio: megaTAL Technology, Research Publications
  • Table 10.16 bluebird bio: Funding Instances
  • Table 10.17 bluebird bio: Partnerships & Collaborations
  • Table 10.18 Sangamo Therapeutics: Funding Instances
  • Table 10.19 Sangamo Therapeutics: Partnerships & Collaborations
  • Table 10.20 Cogent Biosciences: Funding Instances
  • Table 10.21 Cogent Biosciences: Partnerships & Collaborations
  • Table 10.22 Celyad Oncology: Funding Instances
  • Table 10.23 Celyad Oncology: Partnerships & Collaborations
  • Table 10.24 Glycostem: Funding Instances
  • Table 10.25 Glycostem: Partnerships & Collaborations
  • Table 10.26 Intrexon: Funding Instances
  • Table 10.27 Intrexon: Collaborations
  • Table 10.28 Bellicum Pharmaceuticals: Key Switch Technologies
  • Table 10.29 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
  • Table 10.30 Bellicum Pharmaceuticals: Funding Instances
  • Table 10.31 Bellicum Pharmaceuticals: Collaborations
  • Table 10.32 Theravectys: Funding Instances
  • Table 10.33 Technologies For CAR-T Safety Enhancement
  • Table 10.34 Formula Pharmaceuticals: Collaborations
  • Table 11.1 CAR-T Cell Therapy Market: List of Partnerships and Collaborations, 2005-2020 (till October)
  • Table 12.1 CAR-T Cell Therapies: Funding and Investments, 2000-2020 (till October)
  • Table 12.2 CAR-T Cell Therapies Summary of Investments
  • Table 13.1 Assessment Strategies for Different Manufacturing Processes
  • Table 13.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 13.3 Cell Therapy Manufacturing: Companies with In-house Capabilities
  • Table 13.4 Cell Therapy Manufacturing: Contract Manufacturers
  • Table 14.1 Price of Marketed Gene / Cell Therapies
  • Table 14.2 Price of Marketed Targeted Drugs
  • Table 14.3 CAR-T Cell Therapies: Expert Opinions on Pricing
  • Table 14.4 CAR-T Cell Therapies: Reimbursement Landscape
  • Table 15.1 CAR-T Cell Therapies: List of Forecasted Molecules
  • Table 15.2 KYMRIAH® (Novartis): Net Present Value (USD Million)
  • Table 15.3 KYMRIAH® (Novartis): Value Creation Analysis (USD Million)
  • Table 15.4 YESCARTA® (Gilead Sciences): Net Present Value (USD Million)
  • Table 15.5 YESCARTA® (Gilead Sciences): Value Creation Analysis (USD Million)
  • Table 15.6 TECARTUS®: (Gilead Sciences): Net Present Value (USD Million)
  • Table 15.7 TECARTUS®: (Gilead Sciences): Value Creation Analysis (USD Million)
  • Table 15.8 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Net Present Value (USD Million)
  • Table 15.9 BREYANZI® / Lisocabtagene Maraleucel / JCAR017JCAR017 (Bristol Myers Squibb / Juno Therapeutics): Value Creation Analysis (USD Million)
  • Table 15.10 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Net Present Value (USD Million)
  • Table 15.11 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Value Creation Analysis (USD Million)
  • Table 15.12 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen): Net Present Value (USD Million)
  • Table 15.13 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech/ Janssen): Value Creation Analysis (USD Million)
  • Table 15.14 MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
  • Table 15.15 MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
  • Table 15.16 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
  • Table 15.17 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
  • Table 15.18 CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
  • Table 15.19 CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
  • Table 15.20 AUTO1 (Autolus): Net Present Value (USD Million)
  • Table 15.21 AUTO1 (Autolus): Value Creation Analysis (USD Million)
  • Table 15.22 AUTO3 (Autolus): Net Present Value (USD Million)
  • Table 15.23 AUTO3 (Autolus): Value Creation Analysis (USD Million)
  • Table 15.24 GPC3 CAR-T (Shanghai Genechem): Net Present Value (USD Million)
  • Table 15.25 GPC3 CAR-T (Shanghai Genechem): Value Creation Analysis (USD Million)
  • Table 15.26 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
  • Table 15.27 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
  • Table 15.28 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
  • Table 15.29 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
  • Table 15.30 CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
  • Table 15.31 CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
  • Table 15.32 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
  • Table 15.33 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicineTechnology): Value Creation Analysis (USD Million)
  • Table 15.34 PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
  • Table 15.35 PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USDMillion)
  • Table 15.36 TBI-1501 (Takara Bio): Net Present Value (USD Million)
  • Table 15.37 TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
  • Table 15.38 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
  • Table 15.39 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
  • Table 15.40 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD
  • Table 15.41 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
  • Table 15.42 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
  • Table 15.43 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
  • Table 15.44 CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
  • Table 15.45 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
  • Table 15.46 EGFR CAR-T (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
  • Table 15.47 EGFR CAR-T (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
  • Table 15.48 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
  • Table 15.49 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
  • Table 15.50 PBCAR269A (Precision BioSciences and Servier): Net Present Value (USD Million)
  • Table 15.51 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
  • Table 15.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
  • Table 15.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
  • Table 15.54 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
  • Table 15.55 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
  • Table 15.56 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Net Present Value (USD Million)
  • Table 15.57 P-BCMA-101 (Poseida Therapeutics / California Institute for RegenerativeMedicine): Value Creation Analysis (USD Million)
  • Table 16.1 KYMRIAH®: Drug Overview
  • Table 16.2 YESCARTA®: Drug Overview
  • Table 17.1 Autolus: Company Profile
  • Table 17.2 bluebird bio: Company Profile
  • Table 17.3 CARsgen Therapeutics: Company Profile
  • Table 17.4 Celgene: Company Profile
  • Table 17.5 Cellectis: Company Profile
  • Table 17.6 Cellular Biomedicine Group: Company Profile
  • Table 17.7 Innovative Cellular Therapeutics: Company Profile
  • Table 17.8 Kite Pharma: Company Profile
  • Table 17.9 Kuur Therapeutics: Company Profile
  • Table 17.10 Noile-Immune Biotech: Company Profile
  • Table 17.11 Novartis: Company Profile
  • Table 17.12 Shanghai Genechem: Company Profile
  • Table 17.13 Sinobioway Cell Therapy: Company Profile
  • Table 17.14 Takara Bio: Company Profile
  • Table 17.15 Ziopharm Oncology: Company Profile
  • Table 20.1 CAR-T Cell Therapies: Distribution by Type of Developer
  • Table 20.2 CAR-T Cell Therapies: Distribution by Phase of Development
  • Table 20.3 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
  • Table 20.4 CAR-T Cell Therapies: Distribution by Popular Target Indications
  • Table 20.5 CAR-T Cell Therapies: Distribution by Popular Target Antigen
  • Table 20.6 CAR-T Cell Therapies: Distribution by Source of T-Cells
  • Table 20.7 CAR-T Cell Therapies: Distribution by Route of Administration
  • Table 20.8 CAR-T Cell Therapies: Distribution by Dose Frequency
  • Table 20.9 CAR-T Cell Therapies: Distribution by Target Patient Segment
  • Table 20.10 CAR-T Cell Therapies: Distribution by Type of Therapy
  • Table 20.11 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Phase of Development
  • Table 20.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
  • Table 20.13 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
  • Table 20.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
  • Table 20.15 CAR-T Cell Therapies: Popular Targets in Hematological Cancer
  • Table 20.16 CAR-T Cell Therapies: Popular Targets in Solid Tumor
  • Table 20.17 CAR-Construction: Analysis by Generation of CAR-T Therapies
  • Table 20.18 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
  • Table 20.19 CAR-Construction: Analysis by Type of Vector
  • Table 20.20 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
  • Table 20.21 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
  • Table 20.22 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
  • Table 20.23 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
  • Table 20.24 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 20.25 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
  • Table 20.26 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 20.27 Partnerships and Collaborations: Distribution by Individual Products
  • Table 20.28 Partnerships and Collaborations: Most Active Industry Players
  • Table 20.29 Partnerships and Collaborations: Most Active Non-Industry Players
  • Table 20.30 Partnerships and Collaborations: Most Active Contract Manufacturers
  • Table 20.31 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
  • Table 20.32 Partnerships and Collaborations: Regional Distribution
  • Table 20.33 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 20.34 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre 2013-2020 (till October)
  • Table 20.35 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2013-2020 (USD Million)
  • Table 20.36 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Table 20.37 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Table 20.38 Most Active Players: Distribution by Number of Instances
  • Table 20.39 Funding and Investments: Distribution by Types of Investor
  • Table 20.40 Most Active Players: Distribution by Number of Instances
  • Table 20.41 Funding and Investment Analysis: Distribution by Geography
  • Table 20.42 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
  • Table 20.43 Overall CAR-T Cell Therapies Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 20.44 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
  • Table 20.45 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
  • Table 20.46 CAR-T Cell Therapies Market: Key Players, 2025 and 2030 (USD Billion)
  • Table 20.47 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
  • Table 20.48 KYMRIAH® (Novartis) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.49 YESCARTA® (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.50 TECARTUS® (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.51 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.52 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.53 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, Conservative,
  • Table 20.54 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.55 Descartes-11 (Cartesian Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.56 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.57 AUTO1 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.58 AUTO3 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.59 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.60 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.61 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.62 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.63 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.64 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.65 TBI-1501 (Takara Bio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.66 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.67 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.68 BinD19 (Shenzhen BinDeBio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.69 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.70 EGFR CAR-T (The Beijing Pregene Science and Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.71 Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.72 PBCAR269A (Precision BioSciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.73 CD123 CAR-T Cells (Chongqing Precision Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.74 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
  • Table 20.75 P-BCMA-101 (Poseida Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. AbbVie
  • 3. AbCellera
  • 4. AbCheck
  • 5. AbClon
  • 6. Abeona Therapeutics
  • 7. Abzena
  • 8. Academy of Military Medical Sciences (AMMS)
  • 9. Acibadem Altunizade Hospital
  • 10. Acibadem University
  • 11. ACROBiosystems
  • 12. Adaptimmune
  • 13. Adicet Bio
  • 14. Adimab
  • 15. Advanced Cell Therapy Laboratory (ACTL)
  • 16. Advent Bioservices
  • 17. Aeon Biotherapeutics
  • 18. Affiliated Hospital of Jiangnan University
  • 19. Affiliated Hospital to Academy of Military Medical Sciences
  • 20. AffyImmune Therapeutics
  • 21. AgenTus Therapeutics
  • 22. Agilent Technologies
  • 23. Agreen Biotech
  • 24. Alberta Cell Therapy Manufacturing (ACTM)
  • 25. Alexandria Real Estate Equities
  • 26. Allele Biotechnology and Pharmaceuticals
  • 27. Allife Medicine
  • 28. Allogene Therapeutics
  • 29. Altor Bioscience
  • 30. Amgen
  • 31. Angel Biotechnology
  • 32. Anhui Anke Biotechnology
  • 33. Anhui Provincial Hospital
  • 34. ANTAGENE
  • 35. Anterogen
  • 36. Arbele
  • 37. Argos Therapeutics
  • 38. Artiva Biotherapeutics
  • 39. Aspire Health Science
  • 40. Astellas Pharma
  • 41. Astero Bio
  • 42. Atara Biotherapeutics
  • 43. Atossa Therapeutics
  • 44. Aurora Biopharma
  • 45. Autolus
  • 46. Avacta
  • 47. Avalon GloboCare
  • 48. Bambino Gesù Hospital and Research Institute
  • 49. Baxalta
  • 50. Baylor College of Medicine
  • 51. Be The Match BioTherapies
  • 52. Beam Therapeutics
  • 53. Beijing 302 Hospital
  • 54. Beijing Biohealthcare Biotechnology
  • 55. Beijing Boren Hospital
  • 56. Beijing Cancer Hospital
  • 57. Beijing Children's Hospital
  • 58. Beijing Doing Biomedical Technology
  • 59. Beijing HuiNengAn Biotech
  • 60. Beijing Immunochina Medical Science & Technology
  • 61. Beijing Lu Daopei Hospital
  • 62. Beijing Mario Biotech
  • 63. Beijing Sanbo Brain Hospital
  • 64. Beijing Sanwater Biological Technology
  • 65. Beijing Tsinghua Chang Gung Hospital
  • 66. Beijing Yimiao Shenzhou Pharmaceutical
  • 67. Bellicum Pharmaceuticals
  • 68. Beth Israel Deaconess Medical Center (BIDMC)
  • 69. Bio Elpida
  • 70. BioAtla
  • 71. BioCardia
  • 72. Bioceltech Therapeutics
  • 73. Bio-Gene Technology
  • 74. Bioinova
  • 75. BioLife Solutions
  • 76. Biological & Cellular GMP Manufacturing Facility
  • 77. BioNTech
  • 78. BioRestorative Therapies
  • 79. Biosceptre International
  • 80. BioTherapeutics Unit (BTU)
  • 81. bluebird bio
  • 82. Bone Therapeutics
  • 83. Boya Jiyin
  • 84. BoYuan RunSheng Pharma (Hangzhou)
  • 85. Bristol Myers Squibb
  • 86. Cabaret Biotech
  • 87. Calibr
  • 88. California Institute for Regenerative Medicine
  • 89. Cancer Research UK
  • 90. Cancer Prevention Research Institute of Texas
  • 91. Capricor Therapeutics
  • 92. Carina Biotech
  • 93. Carlos III Health Institute (Instituto de Salud Carlos III)
  • 94. CARsgen Therapeutics
  • 95. Cartesian Therapeutics
  • 96. Cartherics
  • 97. Case Comprehensive Cancer Center
  • 98. Case Western Reserve University
  • 99. Casebia Therapeutics
  • 100. Celdara Medical
  • 101. Celgene
  • 102. Cell and Gene Therapy Catapult
  • 103. Cell Design Labs
  • 104. Cell Manufacturing Technologies (CMaT)
  • 105. Cell Therapies Core
  • 106. Cell Therapy and Regenerative Medicine
  • 107. Cell Therapy Manufacturing Cooperative Research Centre (CTM CRC)
  • 108. Cell Therapy Suite
  • 109. Cellectis
  • 110. CELLforCURE
  • 111. Cellin Technologies
  • 112. Cells for Sight Stem Cell Therapy Research Unit
  • 113. Cellular Biomedicine Group (CBMG)
  • 114. Cellular Therapy Core (CTC)
  • 115. Cellular Therapy Integrated Services (CTIS)
  • 116. Celyad Oncology
  • 117. Center for Cell and Gene Therapy
  • 118. Center for Gene and Cell Processing (CGCP)
  • 119. Center for International Blood and Marrow Transplant Research
  • 120. Center of Excellence for Cellular Therapy (C3i)
  • 121. Central South University
  • 122. Centre for Biological Engineering
  • 123. Centre for Cell and Vector Production (CCVP)
  • 124. Centre for Cell Manufacturing Ireland (CCMI)
  • 125. Centre for Stem Cell Research (CSCR)
  • 126. Changhai Hospital
  • 127. Changshu Frist People's Hospital
  • 128. Changzheng Hospital
  • 129. Children's Hospital of Philadelphia
  • 130. Children's GMP / GMP facility St. Jude Children's Research Hospital
  • 131. Children's Hospital and Health System Foundation
  • 132. Children's Hospital of Fudan University
  • 133. Children's Hospital of Philadelphia
  • 134. Children's Mercy Hospital Kansas City
  • 135. China (Nanjing) Cell Valley (CNCV)
  • 136. China Immunotech (Beijing) Biotechnology
  • 137. China Meitan General Hospital
  • 138. China Regenerative Medicine International (CRMI)
  • 139. Chinese Academy of Sciences
  • 140. Chinese PLA General Hospital
  • 141. Chongqing Precision Biotech
  • 142. City of Hope Medical Center
  • 143. City of Hope National Medical Center
  • 144. Cleans Cells
  • 145. Clinical Cell and Vaccine Production Facility (CVPF)
  • 146. Clinical Research Facility
  • 147. Cognate BioServices
  • 148. Columbia University
  • 149. Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF)
  • 150. Cook Myosite
  • 151. Corondo Biosciences
  • 152. Creative Biolabs
  • 153. CRISPR Therapeutics
  • 154. Cryoport
  • 155. CSIRO
  • 156. CTI Clinical Trial and Consulting Services
  • 157. CureSearch for Children's Cancer
  • 158. CytoLumina Technologies
  • 159. CytoMed Therapeutics
  • 160. Cytopeutics
  • 161. Dana-Farber / Harvard Cancer Center
  • 162. Dana-Farber Cancer Institute
  • 163. Dartmouth College
  • 164. Delenex Therapeutics
  • 165. Dendreon
  • 166. DLR German Aerospace Center
  • 167. Dongguan People's Hospital
  • 168. Duke University
  • 169. Editas Medicine
  • 170. Eli Lilly
  • 171. Emory Personalized Immunotherapy Core
  • 172. Endocyte
  • 173. Eureka Therapeutics
  • 174. Eutilex
  • 175. EXUMA Biotechnology
  • 176. Fate Therapeutics
  • 177. Federal Research Institute of Pediatric Hematology
  • 178. FetoLumina Technologies
  • 179. First Affiliated Hospital of Chengdu Medical College
  • 180. First Affiliated Hospital of Chongqing Medical University
  • 181. First Affiliated Hospital of Harbin Medical University
  • 182. First Affiliated Hospital of Wenzhou Medical University
  • 183. First Affiliated Hospital of Zhejiang University
  • 184. First Hospital of Jilin University
  • 185. First People's Hospital of Foshan
  • 186. Five Prime Therapeutics
  • 187. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • 188. Fondo Social La Caixa
  • 189. Fondos ARI (Assistencia Recerca Intensiva)
  • 190. Forevertek Biotechnology
  • 191. Formula Pharmaceuticals
  • 192. Fosun Kite Biotechnology
  • 193. Fosun Pharma
  • 194. Foundation for Biomedical Research and Innovation at Kobe
  • 195. Fraunhofer Institute for Cell Therapy and Immunology
  • 196. Fred Hutchinson Cancer Research Center
  • 197. Froceth
  • 198. Fujian Medical University
  • 199. Fujifilm
  • 200. Fundamenta Therapeutics
  • 201. Gamida Cell
  • 202. Gates Biomanufacturing Facility
  • 203. GC Pharma
  • 204. GE Research
  • 205. GE Healthcare Life Sciences
  • 206. GenCure
  • 207. Gene and Cell Therapy Lab
  • 208. Genentech
  • 209. General Hospital of People's Liberation Army (PLAGH)
  • 210. GenIbet Biopharmaceuticals
  • 211. Genus Oncology
  • 212. Gilead Sciences
  • 213. GlaxoSmithKline
  • 214. Glycostem Therapeutics
  • 215. GlyTherix
  • 216. Gracell Biotechnologies
  • 217. Great Ormond Street Hospital for Children (GOSH)
  • 218. Guangdong General Hospital
  • 219. Guangdong Zhaotai InVivo Biomedicine
  • 220. Guangzhou Eighth People's Hospital
  • 221. Guangzhou Anjie Biomedical Technology
  • 222. Guangzhou First People's Hospital
  • 223. Guy's and St Thomas' Facility
  • 224. H. Lee Moffitt Cancer Center and Research Institute
  • 225. Harvard University
  • 226. Hebei Senlang Biotechnology
  • 227. Hebei Yanda Lu Daopei Hospital
  • 228. Hefei Binhu Hospital
  • 229. Hefei First People's Hospital
  • 230. Helix BioPharma
  • 231. Henan Cancer Hospital
  • 232. Henan Hualong Biotech
  • 233. Henan Provincial People's Hospital
  • 234. Histocell
  • 235. Hitachi Chemical Advanced Therapeutics Solutions
  • 236. Holostem Terapie Avanzate
  • 237. Horizon Discovery
  • 238. Hrain Biotechnology
  • 239. HuaDao (Shanghai) Biomedical
  • 240. Huaian First People's Hospital
  • 241. Huazhong University of Science and Technology
  • 242. Hunan Provincial People's Hospital
  • 243. Hunan Yongren Medical Innovation
  • 244. Hunan Zhaotai Yongren Biotech
  • 245. iCAR Bio Therapeutics
  • 246. iCarTAB BioMed
  • 247. iCell Gene Therapeutics
  • 248. Icell Kealex Therapeutics
  • 249. ICON
  • 250. Immetacyte
  • 251. Immune Therapeutics
  • 252. Immunovative Therapies
  • 253. Imperial College London
  • 254. Inhibrx
  • 255. Innovative Cellular Therapeutics
  • 256. Institut Curie
  • 257. Institute of Cancer Research
  • 258. Institute of Hematology & Blood Diseases Hospital
  • 259. Institute of Translational Health Sciences
  • 260. Intellia Therapeutics
  • 261. Interdisciplinary Stem Cell Institute
  • 262. International Stem Cell
  • 263. Intrexon
  • 264. Invectys
  • 265. Janssen
  • 266. Japanese Society for Regenerative Medicine
  • 267. Jiangsu Province Hospital of Traditional Chinese Medicine
  • 268. Jiangyin People's Hospital
  • 269. Jichi Medical University
  • 270. Jingjiang People's Hospital
  • 271. Jingzhou Central Hospital
  • 272. Jiujiang University Affiliated Hospital
  • 273. John Goldman Centre for Cellular Therapy
  • 274. Jonsson Comprehensive Cancer Center
  • 275. Juno Therapeutics
  • 276. Juventas Cell Therapy
  • 277. JW Therapeutics
  • 278. Kadimastem
  • 279. KAEDI
  • 280. Karolinska institute
  • 281. KBI Biopharma
  • 282. Kecellitics Biotech
  • 283. Kiadis Pharma
  • 284. King's College London
  • 285. Kite Pharma
  • 286. Kurr Therapeutics
  • 287. Laboratory for Cell and Gene Medicine
  • 288. Legend Biotech
  • 289. Leucid Bio
  • 290. Leukemia & Lymphoma Society
  • 291. Leukemia Research Foundation
  • 292. Lianyungang Hospital Affiliated Bengbu Medical College
  • 293. Life Technologies
  • 294. Liminatus Pharma
  • 295. Lineage Cell Therapeutics
  • 296. Lion TCR
  • 297. Living Pharma
  • 298. Longeveron
  • 299. Lonza
  • 300. Loughborough University
  • 301. Loyola University Medical Center
  • 302. LUMICKS
  • 303. MabQuest
  • 304. MabVax Therapeutics Holdings
  • 305. Malaghan Institute of Medical Research
  • 306. Marino Biotechnology
  • 307. Marker Therapeutics
  • 308. Massachusetts General Hospital
  • 309. MaSTherCell
  • 310. Max Delbrück Center for Molecular Medicine
  • 311. MaxCyte
  • 312. McMaster University
  • 313. McMaster University- Biomedical Engineering and Advanced Manufacturing (BEAM)
  • 314. MD Anderson Cancer Center
  • 315. Medical College of Wisconsin
  • 316. MedImmune
  • 317. MEDINET
  • 318. Medipost
  • 319. Medisix Therapeutics
  • 320. MedStar Georgetown University Hospital
  • 321. Memorial Sloan Kettering Cancer Center
  • 322. Merck
  • 323. Mesoblast
  • 324. Mie University
  • 325. Miller School of Medicine
  • 326. Miltenyi Biomedicine
  • 327. Minerva Biotechnologies
  • 328. MingJu Therapeutics
  • 329. Minovia Therapeutics
  • 330. Moffitt Cancer Center
  • 331. Molecular and Cellular Therapeutics
  • 332. MolMed
  • 333. Mustang Bio
  • 334. Nanfang Hospital of Southern Medical
  • 335. Nanjing Bioheng Biotech
  • 336. Nanjing Children's Hospital
  • 337. Nanjing KAEDI Biotech
  • 338. NantKwest
  • 339. National Cancer Center Japan
  • 340. National Cancer Institute
  • 341. National Heart, Lung, and Blood Institute
  • 342. National Institutes of Health
  • 343. National Marrow Donor Program
  • 344. National University of Ireland Galway
  • 345. NeoSTEM
  • 346. Netherlands Cancer Institute
  • 347. Neuralstem
  • 348. Newcastle Advanced Therapies
  • 349. New Jersey Innovation Institute (NJII)
  • 350. NHS Blood and Transplant
  • 351. Nikon CeLL innovation
  • 352. Ningbo Cancer Hospital
  • 353. NIPRO
  • 354. Nkarta
  • 355. Nohla Therapeutics
  • 356. Noile-Immune Biotech
  • 357. Notch Therapeutics
  • 358. Novadip
  • 359. Novartis
  • 360. Obsidian Therapeutics
  • 361. Oncodesign Biotechnology
  • 362. Oncora Medical
  • 363. ONCOTracker
  • 364. OnCyte
  • 365. oNKo-innate
  • 366. ONO Pharmaceutical
  • 367. Opus Bio
  • 368. Orgenesis
  • 369. Ospedale Pediatrico Bambino Gesù (OPBG)
  • 370. Otsuka Pharmaceutical
  • 371. Ottawa Hospital Research Institute
  • 372. Oxford BioMedica
  • 373. Oxford MEStar and AK (Suzhou) Biomedical
  • 374. panCELLa
  • 375. Parker Institute for Cancer Immunotherapy
  • 376. Peking Union Medical College Hospital
  • 377. Peking University
  • 378. Peking University People's Hospital
  • 379. PeproMene Bio
  • 380. PersonGen BioTherapeutics
  • 381. Peter MacCallum Cancer Centre
  • 382. Pfenex
  • 383. PharmaBio
  • 384. Pharmicell
  • 385. Phio Pharmaceuticals
  • 386. Pinze Lifetechnology
  • 387. Pluristem Therapeutics
  • 388. Poseida Therapeutics
  • 389. Praxis Pharmaceutical
  • 390. Precision Biosciences
  • 391. Pregenen
  • 392. Princess Margaret Hospital
  • 393. ProMab Biotechnologies
  • 394. Promethera Biosciences
  • 395. Protheragen
  • 396. Provia Laboratories
  • 397. Purdue University
  • 398. PureTech Health
  • 399. Q-Gen Cell Therapeutics
  • 400. QIMR Berghofer Medical Research Institute
  • 401. Rayne Cell Therapy Suite (King's College London)
  • 402. Regeneron Pharmaceuticals
  • 403. ReNeuron
  • 404. RenJi Hospital
  • 405. Research and Development Center for Cell Therapy (RDC)
  • 406. resTORbio
  • 407. Rexgenero
  • 408. Riyadh Pharmaceutical
  • 409. Rockland Immunochemicals
  • 410. Roger Williams Medical Center
  • 411. Roslin Cells
  • 412. Roswell Park Cancer Institute
  • 413. Royal Adelaide Hospital Cancer Centre
  • 414. Rubius Therapeutics
  • 415. Ruijin Hospital
  • 416. Russian Direct Investment Fund
  • 417. S.Biomedics
  • 418. Samsung BioLogics
  • 419. San Diego Regenerative Medicine Institute
  • 420. Sangamo Therapeutics
  • 421. Scientific and Technological Research Council of Turkey
  • 422. SCM Lifescience
  • 423. Scotia Biologics
  • 424. Scottish National Blood Transfusion Service (SNBTS)
  • 425. Scripps Research
  • 426. Seattle Cancer Care Alliance
  • 427. Seattle Children's Hospital
  • 428. Seattle Children's Research Institute
  • 429. Second Affiliated Hospital of Guangzhou Medical University
  • 430. Second Affiliated Hospital of Nanchang University
  • 431. Second Affiliated Hospital of Xi'an Jiaotong University
  • 432. Second Military Medical University
  • 433. Second Xiangya Hospital of Central South University
  • 434. Sensei Biotherapeutics
  • 435. Servier
  • 436. Shangai Cancer Institute (SCI)
  • 437. Shanghai Tenth People's Hospital
  • 438. Shanghai Sixth People's Hospital
  • 439. Shanghai Biomed-union Biotechnology
  • 440. Shanghai Bioray Laboratory
  • 441. Shanghai Cell Therapy Group
  • 442. Shanghai Cell Therapy Research Institute
  • 443. Shanghai Changzheng Hospital
  • 444. Shanghai Chest Hospital
  • 445. Shanghai Children's Medical Center
  • 446. Shanghai East Hospital
  • 447. Shanghai GeneChem
  • 448. Shanghai International Medical Center
  • 449. Shanghai Jiao Tong University School of Medicine
  • 450. Shanghai Longyao Biotechnology
  • 451. Shanghai PerHum Therapeutics
  • 452. Shanghai Public Health Clinical Center (SPHCC)
  • 453. Shanghai Tongren Hospital
  • 454. Shanghai Tongji Hospital
  • 455. Shanghai UniCAR-Therapy Bio-Medicine Technology
  • 456. Shanghai Zhongshan Hospital
  • 457. Sheba Medical Center
  • 458. Shenzhen Binder Biotechnology
  • 459. Shenzhen Children's Hospital
  • 460. Shenzhen Geno-immune Medical Institute
  • 461. Shenzhen Hospital of Southern Medical University
  • 462. Shenzhen Institute for Innovation and Translational Medicine
  • 463. Shenzhen Second People's Hospital
  • 464. Shenzhen University (SZU)
  • 465. ShiJiaZhuang Zhongxi Children Hospital
  • 466. Sichuan University
  • 467. Sidney Kimmel Cancer Center
  • 468. Simcere Pharmaceutical
  • 469. Sinobioway Cell Therapy
  • 470. Sorrento Therapeutics
  • 471. SOTIO
  • 472. South London and Maudsley NHS Foundation Trust
  • 473. Southern Medical University
  • 474. SpringWorks Therapeutics
  • 475. St. Baldrick's Foundation
  • 476. St. Jude Children's Research Hospital
  • 477. St. Michael's Hospital
  • 478. Stage Cell Therapeutics
  • 479. Stanford University
  • 480. Stem Cell Institute
  • 481. Stemedica Cell Technologies
  • 482. Stemmatters
  • 483. Stempeutics Research
  • 484. Stony Brook University
  • 485. Stratophase
  • 486. Sumitomo Dainippon Pharma
  • 487. Sun Yat-Sen University
  • 488. Suzhou Municipal Hospital
  • 489. Sydney Cell and Gene Therapy
  • 490. Synthace
  • 491. SZU General Hospital
  • 492. Takara Bio
  • 493. Takeda Pharmaceutical
  • 494. Tang Du Hospital
  • 495. Targazyme
  • 496. TC BioPharm
  • 497. Tel Aviv Sourasky Medical Centre (Ichilov)
  • 498. TeneoBio
  • 499. Terumo BCT
  • 500. Tessa Therapeutics
  • 501. Texas Children's Hospital
  • 502. The Affiliated Hospital of Guizhou Medical University
  • 503. The Affiliated Drum Tower Hospital of Nanjing University Medical School
  • 504. The Beijing Pregene Science and Technology
  • 505. The First Affiliated Hospital of Anhui Medical University
  • 506. The First Affiliated Hospital of Guangdong Pharmaceutical University
  • 507. The First Affiliated Hospital of Kunming Medical University
  • 508. The First Affiliated Hospital of Nanchang University
  • 509. The First Affiliated Hospital of Soochow University
  • 510. The First Affiliated Hospital of Zhengzhou University
  • 511. The First Affiliated Hospital with Nanjing Medical University
  • 512. The First People's Hospital of Yuhang District
  • 513. The First People's Hospital of Yunnan
  • 514. The Health Sciences Authority
  • 515. The Islet and Cellular Transplant Facility
  • 516. The Krembil Good Manufacturing Practice Cell Facility
  • 517. The Ohio State University
  • 518. The Philip S. Orsino Cell Therapy Facility
  • 519. The Pregene ShenZhen Biotechnology
  • 520. The Second Affiliated Hospital of Chongqing Medical University
  • 521. The Second Affiliated Hospital of Hainan Medical University
  • 522. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  • 523. The Second Hospital of Anhui Medical University
  • 524. The Second Hospital of Hebei Medical University
  • 525. The Second Hospital of Nanjing Medical University
  • 526. The Second Military Medical University (SMMU)
  • 527. The Second People's Hospital of Huai'an
  • 528. The Seventh Affilliated Hospital
  • 529. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 530. The Sixth Affiliated Hospital of Wenzhou Medical University
  • 531. The Third Affiliated Hospital of Southern Medical University
  • 532. The Wistar Institute
  • 533. Therapeutic Cell Production Core (TCPC)
  • 534. ThermoFisher
  • 535. Third Military Medical University
  • 536. Tianjin Medical University Cancer Institute and Hospital
  • 537. Tianjin Pharmacn Medical Technology
  • 538. Tianjin People's Hospital
  • 539. TILT Biotherapeutics
  • 540. Timmune Biotech
  • 541. Tmunity Therapeutics
  • 542. Tongji University
  • 543. Toni Stephenson Lymphoma Center
  • 544. ToolGen
  • 545. Torque Pharmaceuticals
  • 546. TrakCel
  • 547. Transgene
  • 548. Transposagen Biopharmaceuticals
  • 549. TreeFrog Therapeutics
  • 550. TriArm Therapeutics
  • 551. Trinity College
  • 552. Tri-Service General Hospital
  • 553. TVAX Biomedical
  • 554. UC Davis Good Manufacturing Practice Laboratory
  • 555. UCLA Human Gene and Cell Therapy Facility (HGCTF)
  • 556. UNC Lineberger Comprehensive Cancer Center
  • 557. Union Stem Cell & Gene Engineering
  • 558. United States Department of Defense
  • 559. University College London
  • 560. University Health Network (UHN)
  • 561. University Hospital Basel
  • 562. University Hospital Heidelberg
  • 563. University Hospital Würzburg
  • 564. University of Birmingham
  • 565. University of California
  • 566. University of Cologne
  • 567. University of Colorado
  • 568. University of Florida
  • 569. University of Manchester
  • 570. University of Miami
  • 571. University of Milano-Bicocca
  • 572. University of Minnesota
  • 573. University of North Carolina Lineberger Comprehensive Cancer Center
  • 574. University of Oxford
  • 575. University of Pennsylvania
  • 576. University of Rochester
  • 577. University of Technology Sydney
  • 578. University of Texas
  • 579. University of Toronto
  • 580. University of Utah
  • 581. University of Washington
  • 582. University of Zurich
  • 583. Uppsala University
  • 584. Upstate Stem Cell cGMP Facility
  • 585. UWELL Biopharma
  • 586. V Foundation
  • 587. Vaccinogen
  • 588. Vecura (Karolinska University Hospital)
  • 589. Vericel
  • 590. VetStem Biopharma
  • 591. ViroMed Laboratories
  • 592. Vitruvian Networks
  • 593. Waisman Biomanufacturing
  • 594. Washington University
  • 595. Weill Cornell Medical College of Cornell University
  • 596. Wellington Zhaotai Therapies
  • 597. West China Hospital
  • 598. WindMIL Therapeutics
  • 599. Wuhan Bio-Raid Biotechnology
  • 600. Wuhan Sian Medical Technology
  • 601. Wuhan Union Hospital
  • 602. WuXi AppTec
  • 603. Xiangyang Central Hospital
  • 604. Xijing Hospital
  • 605. Xinqiao Hospital
  • 606. Xuanwu Hospital of Capital Medical University
  • 607. Xuzhou Medical University
  • 608. Yake Biotechnology
  • 609. Yale School of Medicine
  • 610. Yamaguchi University
  • 611. Yan'an Affiliated Hospital of Kunming Medical University
  • 612. Yuan Yi Biotechnology
  • 613. Yunnan Cancer Hospital
  • 614. Zelluna Immunotherapy
  • 615. Zhangjiagang First People's Hospital
  • 616. Zhejiang University (ZJU)
  • 617. Zhujiang Hospital
  • 618. Ziopharm Oncology